Financial review A strong year: the value of the Groups holdings in portfolio companies increased to 552.2m.
Greg Smith Chief Financial Officer Other income for the year increased to 3.6m 2014: Statement of comprehensive income 2.6m.
The increase was primarily due to an increase Overall the Group recorded a profit for the year of in the number of successful corporate finance and 75.1m 2014: 9.5m and a return on Hard NAV, i. e. advisory mandates for portfolio companies, which on the Groups net assets excluding goodwill and resulted in fee income of 1.0m in 2015 2014: 0.1m.
intangible assets and the Oxford Equity Rights asset, Due to managements belief in the growth potential of 84.0m 2014: 17.1m.
of the portfolio and in order to align itself with value creation in the portfolio companies that are the A summary analysis of the Groups financial subject of its mandates, the majority of these fees performance is provided below: 0.7m were received as equity.
This ensures that 2015 2014 as much as possible of the cash raised through such m m financings can be deployed in the development of Net portfolio gains 86.6 22.8 the portfolio companies while increasing the Groups exposure to such companies.
Licensing income 8.1 3.0 Other income 3.6 2.6 The remainder of other income comprises fund management fees as well as consulting and similar Amortisation of intangible fees typically chargeable to its portfolio companies assets and change in fair value of Oxford Equity for services including executive search and selection, Rights asset 7.3 6.7 legal and administrative support.
Fund management fees are received from the Groups three managed Administrative expenses funds, two of which also have the potential to Modern Biosciences plc 2.5 1.8 generate performance fees from successful Administrative expenses investment performance IP Venture Fund and the performance based NETF.
As a result of an extension by its Limited staff incentives and share Partner during the period, the NETFs investment based payments charge 3.4 0.9 period is now anticipated to continue until the Administrative expenses end of 2016, while that of IP Venture Fund ceased all other expenses 11.3 9.0 in 2012.
The fund management fees for both funds Acquisition costs 1.1 reduce following the cessation of their investment Finance income 1.3 0.6 periods.
The results of the Groups third managed fund, IPVFII, are consolidated into those of the Group Profit for the year 75.1 9.5 and accordingly the fund management fees received Net portfolio gains consist primarily of realised are not reflected in the statement of comprehensive and unrealised fair value gains and losses from income.
the Groups equity and debt holdings in spin-out businesses as well as changes in the fair value of its Limited and Limited Liability Partnership interests.
A detailed analysis of fair value gains and losses is provided in the Portfolio review on pages 18 to 29.
30 IP Group plc Annual Report and Accounts for the year ended 31 December 2015 24609-04 Proof 9 5 April 2016 8:01 PM Strategic Report Our Performance The Group continued to receive milestone payments Total Equity Net Assets as a result of Modern Biosciences plcs R&D m alliance and global option and licence agreement 781.9 with Janssen Biotech, Inc. Janssen.
8.0m was received on the achievement of three milestones during 2015 2014: 3.0m: one initial payment.
The 526.2 Group allocated an increased level of capital to the evaluation and development of certain early-stage 336.6 therapeutic programmes, including through its 263.1 781.9m 221.6 subsidiary Modern Biosciences plc MBS, during 2014: 526.2m the year.
The majority of these costs related to the OxteoRx programme that is the subject of the 2011 2012 2013 2014 2015 R&D alliance with Janssen.
All development costs are expensed to the income statement as they are incurred.
MBS continued to benefit from the recovery Profit loss attributable to equity holders of a proportion of the OsteoRx costs through a m Biomedical Catalyst grant, with the net expense being 73.9 72.6 reflected in the statement of comprehensive income.
The Group intends to continue developing a small number of early-stage therapeutic assets.
The Groups administrative expenses, excluding 40.7 those relating to MBS, increased during the period to 14.7m 2014: 9.9m, predominantly due to 73.9m increased headcount, the first full year of the 2014: 9.1m 9.1 increased cost base following the Fusion IP plc 5.5 2011 2012 2013 2014 2015 acquisition in 2014 and the cost of the Groups 2015 Annual Incentive Scheme following the achievement of the 18% maximum target increase in Hard NAV.
The administrative expenses are inclusive of an IFRS 2 Cash, cash equivalents and deposits share-based payments charge totalling 1.5m m 2014: 0.9m relating to the Groups Long-Term 178.8 Incentive Plan and Deferred Bonus Share Plan awards.
This non-cash charge reflects the fair value of services received from employees, measured by reference to the fair value of the share-based payments at the date of award, but has no net impact on the Groups 97.3 total equity or net assets.
60.5 178.8m 47.9 As a result of the Groups two equity capital raisings 2014: 97.3m in the first half of the year which raised 178.8m net 24.1 of expenses, and the resultant increased average 2011 2012 2013 2014 2015 cash balance during the year, the Groups interest receivable during the period increased to 1.3m 2014: 0.6m.
com 24609-04 Proof 9 5 April 2016 8:01 PM Financial review continued Statement of financial position Cash, cash equivalents and shortThe Group ended the period with net assets term deposits Cash attributable to shareholders of 780.4m, representing The principal constituents of the movement in Cash an increase of 254.2m from the position at 1 January during the year are summarised as follows: 2015 526.2m.
As described above, the most 2015 2014 significant contributing factors to the increase in net m m assets during the period were the 178.8m capital raising and the performance of the Groups portfolio Net Cash generated used by operating of holdings in spin-out companies.
Hard net assets, activities i. e. those excluding intangible assets and the Oxford excluding cash flows Equity Rights asset, totalled 714.3m at 31 December from deposits 2.4 6.4 2015 2014: 451.3m.
Net Cash used in At 31 December 2015, the Group held gross cash and investing activities 114.6 35.4 deposits of 178.8m 2014: 97.3m and a diversified Issue of share capital 178.8 97.4 portfolio of equity and debt investments in 99 private Drawdown of debt and publicly listed technology companies 2014: 90. facility 14.9 The value of the Groups holdings in portfolio Acquisition of subsidiary 17.6 companies increased to 552.2m at year end 2014: Movement during period 81.5 73.2 349.9m after net unrealised fair value gains of 86.4m and net investment of 115.3m 2014: 20.7m At 31 December 2015, the Groups Cash totalled net unrealised fair value gain: 37.1m net investment.
178.8m, an increase of 81.5m from a total of 97.3m The Portfolio review on pages 18 to 29 contains a at 31 December 2014 predominantly due to a net detailed description of the Groups portfolio of equity 178.8m increase from the issue of new equity capital and debt investments including key developments and 15.0m through the part drawdown of the 30m and movements during the year.
debt facility provided by the European Investment Bank 14.9m net of expenses, and offset by net The Groups statement of financial position includes investment in the Groups spin-out companies.
goodwill of 57.1m 2014: 57.1m and acquired intangible assets of 10.5m 2014: 16.5m.
38.7m of In July, the Group secured a 30m, 8-year debt the goodwill and entirety of the acquired intangible facility from the European Investment Bank the assets values arose as a result of the Groups EIB.
The facility is to be disbursed in two tranches, acquisition of Fusion IP in 2014.
The remainder of the with the first tranche of 15m having been drawn goodwill balance arose from historical acquisitions down in December 2015.
The facility provides of Techtran Group Limited university partnership IP Group with an additional source of long-term business, 16.3m: 2014: 16.3m and Top Technology capital and represents an evolution in the Groups Ventures Limited venture capital fund management capital structure to support its future growth and business, 2.1m: 2014: 2.1m.
The intangible assets are development.
separately identifiable assets resulting from Fusion The Groups net cash used in investing activities IPs agreements with its partner universities.
The fair increased during 2015, reflecting an increase in value of the intangible assets are to be amortised on investments 2015: 115.9m: 2014: 46.8m but a a straight line basis over each partnerships useful decrease in realisations 2015: 0.6m: 2014: 9.7m.
As described in more detail in the Portfolio review on Due to the nature of its activities, the Group has pages 18 to 29, the Group allocated a total of 75.9m limited current assets or current liabilities other than across 53 portfolio companies during the period its cash and short-term deposit balances, which are 2014: 46.8m: 51 companies and made a 40m considered in more detail below.
32 IP Group plc Annual Report and Accounts for the year ended 31 December 2015 24609-04 Proof 9 5 April 2016 8:01 PM Strategic Report Our Performance No further funds were committed to IP Venture Fund during 2015 2014: 0.3m, which in turn made no investments during the period 2014: 2.7m: eight companies.
The Group received a distribution of 0.6m following IP Venture Fund realising 5.7m from two exits and one partial disposal 2014: 1.1m received on a total 11.1m distributed.
Overall, net cash used in investing activities totalled 114.6m 2014: 35.4m.
Primarily as a result of the income from the milestone payments received by the Group as a result of MBSs agreement with Janssen as noted above, Cash generated by operating activities increased to 2.4m 2014: 6.4m of Cash used by operating activities.
It remains the Groups policy to place cash that is surplus to near-term working capital requirements on short-term and overnight deposits with financial institutions that meet the Groups treasury policy criteria or in low-risk treasury funds rated A or above.
The Groups treasury policy is described in detail in note 2 to the Group financial statements alongside details of the credit ratings of the Groups cash and deposit counterparties.
At 31 December 2015, the Group recognised 7.1m of loans 2014: 4.5m from the Limited Partners of IPVFII, a fund raised during 2013 that is consolidated by the Group.
These loans are repayable only upon IPVFII generating sufficient returns to repay the Limited Partners.
A further 15.0m of non-current liabilities are recognised which arise from the Groups use of the EIB debt facility described above.
At 31 December 2015, the Group had a total of 1.3m 2014: 1.2m held in US Dollars to meet the short-term working capital requirements of its US operations, including capital anticipated to be required by new and existing spin-out company opportunities.
Taxation Since the Groups activities, including its activities in the US, are substantially trading in nature, the Directors continue to believe that the Group qualifies for the Substantial Shareholdings Exemption SSE on chargeable gains arising on the disposal of qualifying holdings and, as such, the Group has continued not to recognise a provision for deferred taxation in respect of uplifts in value on those equity stakes which meet the qualifying criteria.
The Groups unrecognised deferred tax assets and liabilities are set out in note 9 to the financial statements.
